Download PRESS RELEASE BPJS Kesehatan Is The New Hope For People

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Point mutation wikipedia , lookup

Cell-free fetal DNA wikipedia , lookup

Transcript
PRESS RELEASE
BPJS Kesehatan Is The New Hope For People With Hemophilia
Jakarta (10/14/2015): Chasing dreams and ideals might previously be unthinkable for
children with hemophilia. They never asked to be born into hemophiliacs, but that's the
reality needed to be faced by M. Ade Nastyar (18), who are affected by hemophilia.
Hemophilia is a congenital blood disorder where the blood cannot clot by itself normally
because the body cannot make factor VIII. Factor VIII is necessary to help the process of
blood clotting. Just a little small wound could be fatal because the blood would not stop
pouring. In fact, it can cause death if it is not promptly treated.
According to Dr. Dr. Rini Purnamasari, SpA, the division of hematology oncology
physicians child RSU Tangerang, a cure for hemophilia, the clotting factor VIII costs about
Rp 2.5 million per bottle and clotting factor IX approximately Rp. 4.3 million per bottle.
In addition, at the beginning of the treatment of a patient with hemophilia must first ensure
that he has the type of hemophilia, either type A or type B. Haemophilia type A caused by
the body's blood clotting factor VIII deficiency, while type B hemophilia caused by
deficiency of factor IX blood clotting. This factor is a protein in the blood that play a role in
blood clotting process. To note, hemophilia caused by mutations in the gene that produces
the factor VIII and factor IX. This mutation is also known to occur on the X chromosome
BPJS Kesehatan bring new hope to Ade, because they no longer need to weigh up when he
needed injection. Because, now they are already registered as participants and PJS Health.
Coverage of the benefits of health services of BPJS itself does cover Hemophilia, for the
treatment of Hemophilia is great and last a lifetime. According to the Head of Group Public
Communication and Inter-Agency Relations BPJS Kesehatan, Ikhsan, until the month of
service September 2015, BPJS Kesehatan has paid Rp. 68 Billion for hemophilia cases, the
number of cases as many as 19.072 cases.
***
-The EndFor further information contact:
Department of External Communications and Public Relations
BPJS Kesehatan Headquarters
+62 21 424 6063
[email protected]